真性红细胞增多症与原发性血小板增多症:2021年诊断、风险分层与管理更新
该综述更新了PV和ET的诊断、风险分层与治疗。诊断以骨髓形态为基础,PV需JAK2突变,ET约90%有JAK2、CALR或MPL驱动突变。PV中位生存约15年,ET约18年;10年白血病转化率ET<1%、PV 3%。治疗目标是预防血栓出血并发症,PV需放血使血细胞比容<45%并用阿司匹林,高危患者用羟基脲。
要点
- PV诊断需JAK2突变,ET需排除前纤维化骨髓纤维化并检测驱动突变。
- PV风险分高危(年龄>60岁或血栓史)和低危;ET分极低、低、中、高危四层。
- PV所有患者放血保持血细胞比容<45%并用阿司匹林;高危ET/PV用羟基脲。
核心结论
- PV和ET治疗主要目标是预防血栓出血并发症,根据风险分层选择放血、抗血小板或降细胞治疗。
研究设计与样本
- 综述基于文献更新PV和ET的诊断、风险分层与管理,未报告系统检索范围。
主要发现
- PV中位生存约15年,ET约18年;年龄40岁或以下者分别为37年和35年。
- 10年白血病转化率ET<1%,PV为3%。
- ET中JAK2突变者血栓风险更高,但驱动突变未显示影响生存。
关键数值与推荐
- PV高危:年龄>60岁或血栓史;低危:两者均无。
- ET极低危:年龄≤60岁、无血栓史、JAK2野生型;低危:同极低危但JAK2突变;中危:年龄>60岁、无血栓史、JAK2野生型;高危:血栓史或年龄>60岁伴JAK2突变。
- PV放血目标血细胞比容<45%,阿司匹林81 mg每日一次或两次;降细胞一线羟基脲,二线干扰素-α或白消安。
临床怎么用
- PV所有患者放血保持血细胞比容<45%并用阿司匹林(无禁忌时)。
- ET极低危可能无需治疗,低危建议阿司匹林;高危ET和PV推荐降细胞治疗,中危ET非必须。
- PV不推荐芦可替尼,除非严重持续瘙痒或明显脾大且前述药物无效。
局限性
- 需对照研究确认每日两次与每日一次阿司匹林的临床价值及聚乙二醇干扰素和直接口服抗凝药的治疗作用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
DISEASE OVERVIEW: Polycythemia vera (PV) and essential thrombocythemia (ET) are myeloproliferative neoplasms (MPN) respectively characterized by clonal erythrocytosis and thrombocytosis; other disease features include leukocytosis, splenomegaly, thrombosis, bleeding, microcirculatory symptoms, pruritus and risk of leukemic or fibrotic transformation. DIAGNOSIS: Bone marrow morphology remains the cornerstone of diagnosis. In addition, the presence of JAK2 mutation is expected in PV while approximately 90% of patients with ET express mutually exclusive JAK2, CALR or MPL mutations (so called driver mutations). In ET, it is most important to exclude the possibility of prefibrotic myelofibrosis. SURVIVAL: Median survivals are approximately 15 years for PV and 18 years for ET; the corresponding values for patients age 40 or younger were 37 and 35 years. Certain mutations (mostly spliceosome) and abnormal karyotype might compromise survival in PV and ET. Life-expectancy in ET is inferior to the control population. Driver mutations have not been shown to affect survival in ET but risk of thrombosis is higher in JAK2 mutated cases. Leukemic transformation rates at 10 years are estimated at <1% for ET and 3% for PV. THROMBOSIS RISK: In PV, two risk categories are considered: high (age > 60 years or thrombosis history present) and low (absence of both risk factors). In ET, four risk categories are considered: very low (age ≤ 60 years, no thrombosis history, JAK2 wild-type), low (same as very low but JAK2 mutation present), intermediate (age > 60 years, no thrombosis history, JAK2 wild-type) and high (thrombosis history present or age > 60 years with JAK2 mutation). RISK-ADAPTED THERAPY: The main goal of therapy in both PV and ET is to prevent thrombohemorrhagic complications. All patients with PV require phlebotomy to keep hematocrit below 45% and once-daily or twice-daily aspirin (81 mg), in the absence of contraindications. Very low risk ET might not require therapy while aspirin therapy is advised for low risk disease. Cytoreductive therapy is recommended for high-risk ET and PV, but it is not mandatory for intermediate-risk ET. First-line drug of choice for cytoreductive therapy, in both ET and PV, is hydroxyurea and second-line drugs of choice are interferon-α and busulfan. We do not recommend treatment with ruxolutinib in PV, unless in the presence of severe and protracted pruritus or marked splenomegaly that is not responding to the aforementioned drugs. NEW TREATMENT DIRECTIONS: Controlled studies are needed to confirm the clinical outcome value of twice-daily vs once-daily aspirin dosing and the therapeutic role of pegylated interferons and direct oral anticoagulants.
引用
- Tefferi A, Barbui T. Polycythemia vera and essential thrombocythemia: 2021 update on diagnosis, risk-stratification and management. Am J Hematol. 2020. PMID: 32974939. doi:10.1002/ajh.26008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。